Target intelligence / Profile preview

Oxidation-specific epitope (OSE)

Target
OSE
Molecular classification
Other (pattern/epitope, not a traditional protein or receptor family), Damage-associated molecular pattern (DAMP), Modified self-antigen
01

Overview

Oxidation-specific epitopes are neoepitopes generated when endogenous biomolecules (such as lipids, proteins, and lipoproteins) undergo oxidative modification by reactive oxygen species, often as a result of inflammation, metabolic stress, or aging. They are not individual molecules but a heterogeneous set of oxidized molecular structures (such as oxidized phospholipids, malondialdehyde adducts, oxidized cholesteryl esters) that signal cellular or tissue damage. OSEs are recognized by several pattern recognition receptors (PRRs) of the innate immune system, including scavenger receptors (e.g., CD36), toll-like receptors, natural antibodies, and C-reactive protein. Their recognition mediates the clearance of apoptotic cells and damaged debris and can trigger inflammation. Accumulation of OSEs, or disturbed recognition/clearance, has been implicated in the pathogenesis of chronic inflammatory diseases particularly atherosclerosis, as well as in non-alcoholic steatohepatitis and other conditions. OSEs are thus best understood as immunologically relevant oxidation-derived patterns, not as druggable molecular targets.

Other names
OSEoxidation-specific epitopesoxidized neoepitopesDAMPs (as a subset of damage-associated molecular patterns)
02

Mechanism of action

Neutralization of OSEs (by antibodies or immune components); Blockade of OSE recognition by pattern recognition receptors (theoretical/experimental)

03

Biological functions

Immune recognition (by pattern recognition receptors, natural antibodies, complement, etc.)Mediation of apoptotic cell clearanceTriggering of sterile inflammationInduction of proinflammatory gene expression (via PRRs)
04

Disease associations

Cardiovascular disease (notably atherosclerosis)Chronic inflammationNon-alcoholic fatty liver disease and steatohepatitisAge-related macular degenerationSepsis
05

Safety considerations

Targeting OSEs could disrupt physiologic clearance of apoptotic cells, potentially exacerbating autoimmunity or impairing resolution of inflammationImmunomodulation risks (as with any therapy targeting innate immune responses)
06

Biomarkers

Antibody titers to OSEs (e.g., IgM against oxidized LDL, malondialdehyde adducts)Presence of OSEs on oxidized LDL or apoptotic cells (diagnostic marker in research settings)

Beyond the preview

Go deeper on Oxidation-specific epitope (OSE).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oxidation-specific epitope (OSE).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call